The stock of Aldeyra Therapeutics Incorporated (NASDAQ:ALDX) registered an increase of 2.16% in short interest. ALDX’s total short interest was 75,700 shares in September as published by FINRA. Its up 2.16% from 74,100 shares, reported previously. With 38,000 shares average volume, it will take short sellers 2 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Incorporated’s float is 2.61%. About 3,927 shares traded hands. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has risen 40.36% since February 8, 2016 and is uptrending. It has outperformed by 23.87% the S&P500.
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The company has a market cap of $68.38 million. The Company’s principal activities include raising capital and research and development activities. It currently has negative earnings. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
The institutional sentiment decreased to 1.88 in 2016 Q2. Its down 0.32, from 2.2 in 2016Q1. The ratio is negative, as 4 funds sold all Aldeyra Therapeutics Inc shares owned while 4 reduced positions. 2 funds bought stakes while 13 increased positions. They now own 6.07 million shares or 40.87% more from 4.31 million shares in 2016Q1.
Awm Investment Company Inc. holds 1.12% of its portfolio in Aldeyra Therapeutics Inc for 917,810 shares. Perceptive Advisors Llc owns 1.94 million shares or 0.77% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.54% invested in the company for 368,500 shares. The New York-based Knoll Capital Management Lp has invested 0.25% in the stock. Pura Vida Investments Llc, a New York-based fund reported 77,500 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.